Stryker Corporation $SYK Stock Holdings Lifted by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp lifted its position in Stryker Corporation (NYSE:SYK) by 834.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,666 shares of the medical technology company’s stock after acquiring an additional 22,918 shares during the period. Atlantic Union Bankshares Corp’s holdings in Stryker were worth $10,154,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. lifted its stake in Stryker by 17.7% in the second quarter. First Horizon Advisors Inc. now owns 2,894 shares of the medical technology company’s stock valued at $1,146,000 after acquiring an additional 435 shares during the last quarter. Cherry Creek Investment Advisors Inc. acquired a new stake in Stryker in the second quarter valued at approximately $209,000. Beckerman Institutional LLC acquired a new stake in shares of Stryker in the second quarter worth $201,000. NewSquare Capital LLC lifted its stake in shares of Stryker by 93.7% in the second quarter. NewSquare Capital LLC now owns 246 shares of the medical technology company’s stock worth $97,000 after buying an additional 119 shares during the last quarter. Finally, J. W. Coons Advisors LLC raised its stake in Stryker by 145.0% during the 2nd quarter. J. W. Coons Advisors LLC now owns 8,128 shares of the medical technology company’s stock valued at $3,216,000 after purchasing an additional 4,810 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SYK. Needham & Company LLC upped their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research note on Monday. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Fourteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Price Performance

Shares of SYK opened at $357.76 on Thursday. The stock has a market capitalization of $136.82 billion, a P/E ratio of 47.39, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a 50 day moving average of $376.08 and a 200-day moving average of $381.07. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the business earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.